Literature DB >> 20582969

Tigecycline treatment of multi-drug-resistant Corynebacterium jeikeium infection in a child with relapsing and refractory acute lymphoblastic leukemia.

Ener Cagri Dinleyici1, Zeynel Abidin Yargic, Ozcan Bor, Abdurrahman Kiremitci, Gul Durmaz.   

Abstract

Corynebacterium jeikeium has been recognized as an important cause of infection, particularly among neutropenic patients who have central venous catheter (CVC). Routine use of tigecycline in children is not yet approved. Here in we present a child with relapsed-refractory lymphoblastic leukemia who was successfully treated with tigecyline due to multi-drug-resistant C. jeikeium sepsis without removal of CVC. Our case highlights the use of tigecycline where there are no alternatives. Further studies regarding the efficacy and safety of tigecycline in pediatric patients are needed. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20582969     DOI: 10.1002/pbc.22527

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  8 in total

1.  Preliminary experience of tigecycline treatment for infection in children with hematologic malignancies.

Authors:  Shupeng Lin; Chenmei Zhang; Sheng Ye
Journal:  Int J Clin Pharm       Date:  2018-07-26

2.  Antimicrobial susceptibility among Gram-positive organisms collected from pediatric patients globally between 2004 and 2011: results from the Tigecycline Evaluation and Surveillance Trial.

Authors:  Michael Brandon; Michael J Dowzicky
Journal:  J Clin Microbiol       Date:  2013-05-15       Impact factor: 5.948

3.  Preliminary experience with tigecycline treatment for severe infection in children.

Authors:  Sheng Ye; Chenmei Zhang; Shupeng Lin
Journal:  Eur J Pediatr       Date:  2018-07-14       Impact factor: 3.183

4.  Purulent pericarditis with quadruple valve endocarditis.

Authors:  Huliyurdurga S Setty Natrajsetty; Ishwarappa B Vijayalakshmi; Chitra Narasimhan; Cholenahalli N Manjunath
Journal:  Am J Case Rep       Date:  2015-04-23

Review 5.  The Antibiotic Drug Tigecycline: A Focus on its Promising Anticancer Properties.

Authors:  Zhijie Xu; Yuanliang Yan; Zhi Li; Long Qian; Zhicheng Gong
Journal:  Front Pharmacol       Date:  2016-12-02       Impact factor: 5.810

6.  Tigecycline treatment in a liver transplant infant with carbapenem-resistant Escherichia coli infection: Case report.

Authors:  Mei Yang; Hengmiao Gao; Xiaoling Wang; Suyun Qian
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

7.  Tigecycline treatment of infection caused by KPC-producing Escherichia coli in a pediatric patient.

Authors:  Xiaoxing Du; Ying Fu; Yunsong Yu
Journal:  Ann Clin Microbiol Antimicrob       Date:  2013-08-13       Impact factor: 3.944

8.  Central venous catheter-related infections caused by Corynebacterium amycolatum and other multiresistant non-diphtherial corynebacteria in paediatric oncology patients.

Authors:  Ricardo Vianna de Carvalho; Fernanda Ferreira da Silva Lima; Cíntia Silva Dos Santos; Mônica Cristina de Souza; Rondinele Santos da Silva; Ana Luiza de Mattos-Guaraldi
Journal:  Braz J Infect Dis       Date:  2018-08-11       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.